Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Trehalose

D-Trehalose · also known as Trehalose, Natural disaccharide autophagy inducer, Trehalose

Trehalose is a non-reducing disaccharide. In animal and cell studies it can trigger TFEB-linked lysosomal and autophagy responses. At usual oral doses, only a very limited amount of intact trehalose reaches tissues, and there is no reliable human evidence that it induces autophagy in the brain or stabilizes proteins.

Typical dose: Typical doses are 5–15 g/day, dissolved in lukewarm or cool water. At this amount it is carbohydrate intake that has to be counted, not a negligible trace.
Absorption and forms: Trehalose is a non-reducing disaccharide, and trehalase in the small intestine breaks most of it down into glucose. Only a limited amount of intact trehalose enters human tissue, so taking it on an empty stomach cannot guarantee autophagy induction in the brain.

Clinical uses and human evidence

Blood sugar and insulin resistance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Hashemian 2023 · Arch Med Sci · RCT · n=40 — The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial
  2. Yoshizane 2020 · Nutr J · RCT · n=50 — Daily consumption of one teaspoon of trehalose can help maintain glucose homeostasis: a double-blind, randomized controlled trial conducted in healthy volunteers

Inflammation markers (such as CRP)

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Hashemian 2023 · Arch Med Sci · RCT · n=40 — The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial

Mechanisms of action

mTORC1 allosteric inhibition and macroautophagy induction

★☆☆☆☆Mechanism evidence: grade DPrimary target

In cell and animal studies, trehalose can trigger autophagy and TFEB-related responses, but the concentrations used are far higher than oral dosing can reach in tissue. Some effects are independent of mTOR, and the upstream mechanism is still debated. There is no evidence that oral trehalose induces autophagy in humans.

References (3)
  1. DeBosch et al. 2016 · Mouse and cell study: trehalose-related changes in SLC2A, AMPK and hepatic autophagy signaling
  2. Howson et al. 2019 · Rat and primate study: after high oral doses, brain exposure was far below the concentrations commonly used in cell experiments
  3. 2021 cell study · Lysosomal stress can also trigger a TFEB response, and the specific upstream mechanism is disputed

Chaperone relief of ER stress and improved bile acid flow

★☆☆☆☆Mechanism evidence: grade DPrimary target

As a chemical chaperone, trehalose can stabilize some proteins in high-concentration in-vitro experiments. Intact trehalose is hydrolyzed in the gut, and usual oral doses are unlikely to reach the tissue concentrations needed. Brain exposure is also very low in animal pharmacokinetic studies, and its tissue effects in humans have not been studied.

References (2)
  1. Howson et al. 2019 · Animal pharmacokinetic study: after high oral doses, brain trehalose exposure was very low
  2. Human research gap · No reliable study has shown trehalose acting as a chemical chaperone in human tissue at usual oral doses

Safety and drug interactions

People with congenital trehalase deficiency may get osmotic diarrhea or bloating after taking it. People with diabetes need to count the carbohydrate in it toward their total daily calories.
Open in the interactive app ›